





Issue Opens - January 13, 2025 to January 15, 2025

Price Band ₹407 to ₹428 Face Value ₹2 Lot Size 33 Shares

Issue Size ₹698.06 Cr Issue Type Book Built

Issue Size Fresh Issue Offer for Sale

Basis of Allotment Initiation of Refunds

Credit of Shares to Demat

Laxmi Dental Listing Day

1.63.09.766 shares / ₹698.06 Cr

32.24.299 shares / ₹ 138.00 Cr 1.30.85.467 shares / ₹560.06 Cr

Thursday, January 16, 2025

Friday, January 17, 2025

Friday, January 17, 2025

Monday, January 20, 2025

Objects of The Offer



The company plans to use the net proceeds for the following purposes:

- Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the Company up to Rs. 22.98 crores
- Investment in certain Subsidiaries for the repayment/prepayment, in full or in part, of certain outstanding borrowings up to Rs. 4.6 crores?
 Funding the capital expenditure requirements for purchasing new machinery.
- Funding the capital expenditure requirements for purchasing new machinery for the Company up to Rs. 43.50 crores
- Investment in their subsidiary, Bizdent Devices Private Limited, is needed for the capital expenditure requirements for the purchase of new machinery up to Rs. 2.5 crores
- 5. General corporate purposes.

Brief profile of the Directors

Rajesh Vrajial Khakhar is one of the promoters and the Chairperson of the company. He manages international partnerships and business development. With over 30 years of experience, he also directs Bizdent Devices Private Limited, a subsidiary. He received the ICONS award (2020-21) for his contributions to dentistry.

Sameer Kamlesh Merchant is the Managing Director and CEO. He oversees business strategy, operations, and technology initiatives. With 20+ years of experience, he has diversified the companys offerings. Sameer is also involved in Bitdent Devices Private Limited and received various certificates for his expertise.

Sumona Chakraborty is a Non-Executive Director and nominee of OrbiMedAsia. With a tech background and 10+ years of experience, she is currently with OrbiMedAdvisors.

Rajesh Shashikant Dalal is a Non-Executive Independent Director with 34 years of experience in engineering and past roles at OrbiMedAdvisors and Johnson & Johnson.

Anjana Rajendra Grewal is a Non-Executive Independent Director with 23 years of experience in finance and management. She is a professor at SDA Bocconi Asia Center and has worked at several major companies, including Birla Sun Life and Global Trust Bank.

Key Business Operations



Incorporation: Laxmi Dental Limited was incorporated on July 8, 2004, initially as Laxmi Dental Export Private Limited. It has since evolved into India's only end-to-end integrated dental products company.

- a. Product Portfolio: The company offers a wide array of products categorized into three main segments: Dental Laboratories: Custommade crowns and bridges, metal-ceramic restorations, and metalfree restorations like zirconia crowns.
 - Aligner Solutions: Clear aligners (Illusion Aligners), thermoforming sheets, and associated products, including 3D printing resins.
 - c. Pediatric Dental Products: Specialized products for children's dental needs, such as flexible crowns and silver diamine fluoride (SDF) for treating dental caries.

Manufacturing Facilities: Laxmi Dental operates six manufacturing facilities across Maharashtra and Kerala, covering over 147,000 square feat. These facilities are equipped to produce a variety of dental products efficiently. The company is recognized as one of the top two largest dental laboratories in India and the largest exporter of dental laboratory products. It has a vast distribution network that reaches over 22,000 dental clinics across 320 cities in India and exports to more than 95 countries.



total customers served

for aligners in

Below table sets forth contribution of customers of their aligner solutions from tier I, tier II, and tier III cities to total customers served for aligners in the six month period ended September 30, 2024 and Fiscals 2024, 2023, and 2022

total customers served

for aligners in

Fiscal. Fincal 2024 total customers served

for aligners in

number) 961 number) 861

Fiscal

services million) services

22.06%

183.69 11.56%

total customers served

for allieners in

Six menth

Six month

period period 2024 (in (in 94) 2023 (in 2023 (in 2022 (in 2022 (in

ended ended number)

Sentember September 30, 2024 30, 2024 (in 96)

67.42

1.156.79 100.00% 1.914.50 100.00% 1,589.41 100.0014 1.294.78 100.00%

Laboratory Alieser

solutions Others

Total

Tier I 1,810 46,90% 2,348 47,09% 2,109 51,33% 1,027 5 Tier II 1,423 36,87% 1,774 35,58% 1,323 32,20% 704
Tier II 1.423 36.87% 1.774 35.58% 1.323 32.20% 704
Tier III 626 16.22% 864 17.33% 677 16.48% 308

Set forth below is a breakup of our revenue across our various product offerings for

six month period ended September 30, 2024 and Fiscals 2024, 2023 and 2022:								
Revenue Segment	Six month period ended September 30, 2024		Fise	al 2024	Fiscal 2023 Fisc		al 2022	
	Revenue from sale	Percentage	Revenue from sale	Percentage	Revenue from sale	Percentage	Revenue from sale	Percentage

Revenue Segment	Six month period ended September 30, 2024		Fise	al 2024	Fiscal 2023		Fiscal 2022	
	Revenue from sale of goods		Revenue from sale of goods	of	Revenue from sale of roads	of	Revenue from sale of goods	Percentage of Revenue

Segment	ended September 30, 2024					
	Revenue from sale of goods and	of	from sale of goods	from sale of goods	from sale of goods	of

136.47

2	024						
Revenue from sale of goods	of Revenue	Revenue from sale of goods	Percentage of Revenue	Revenue from sale of goods	of Revenue	Revenue from sale of goods	Percentage of Revenue
and services	from sale of goods	and services	from sale of goods	and services	from sale of goods	and services	from sale of goods
(noillim	and services	(in ₹	and services	(in ₹	and services	(neillim	services

Statement of Profit and Loss

Particulars	Six month period ended September 30, 2024	March 31, 2024	March 31, 2023	March 31, 2022
Income				
Revenue from operations	1,167.80	1,935.55	1.616.31	1,368.43
Other Income	11.2	17.09	22.13	12.27
Total Income (A)	1,179.00	1.952.64	1.638.44	1,380.70
II Expenses				
Cost of material consumed	262.39	464.18	306.28	306.37
Purchase of stock-in-trade	24.77	38.35	100.7	100.58
Change in inventories of finished goods	-4.61	-17.64	10.99	-10.39
Employee benefits expenses	383.39	715.11	653.37	530.78
Finance costs	25.99	49.54	40.94	35.67
Depreciation and amortization expenses	67.68	119.36	109.94	83.98
Other expenses	274.53	497.65	455.33	386.96
Total Expenses (B)	1,034.14	1,866.55	1,677.55	1,433.96
Profit/(loss) before tax D = (A-B-C)	211.03	85.24	-42.61	-147.12
Income tax expense				
Current tax	9.72	17.85	1.96	0
Adjustment of tax relating to earlier periods	-0.51	-0.14	0.04	14.51
Deferred tax	19.85	-111.88	-0.12	9.2
Total income tax expense (E)	29.06	-94.17	1.88	23.71
Profit/(loss) after tax F=(D-E)	181.97	179.41	-44.49	-170.83
Share in profit after tax of Joint ventures G	52.51	88.88	6.02	-1.45
Profit/(loss) for the year	234.48	268.29	-38.47	-172.28
Profit/(loss) for the year	227.89	252.39	41.63	-186.73
Earnings/ (Loss) per equity shares				
Basic EPS (INR)	4.39	4.8	-0.77	-3.56
Diluted EPS (INR)	4.39	4.8	-0.77	-3.56

Strengths 8 1



- Market Leadership: Laxmi Dental is recognized as India's only fully integrated dental products company, which allows it to control the entire production process from raw materials to final distribution. This vertical integration enhances efficiency and quality, providing a competitive edge in the market.
- Diverse Product Portfolio: The company offers a wide range of dental products, including custom crowns, bridges, clear aligners, and pediatric dental solutions. This diversity helps mitigate risks associated with reliance on a single product line and caters to various customer needs.
- Strong Growth Potential: The Indian dental market is experiencing significant growth, particularly in segments like custom-made crowns and clear aligners. The clear aligner market is expected to grow at a CAGR of 23%, which positions Laxmi Dental favorably to capitalize on this trend.
- 2.5%, which positions Laximi Dental has ot capitalize on rins trend.
 Extensive Distribution Network: Laximi Dental has established a robust network connecting over 22,000 dental clinics, facilitating widespread adoption of its products and ensuring stable demand. This network also serves as a barrier to entry for potential competitors.
- serves as a parrier to entry for potential competitors.

 **Technological Innovation: The company has embraced digital dentistry and advanced manufacturing technologies, positioning itself at the forefront of industry innovation. This focus on technology enhances operational efficiency and product quality.

Threats

- Niche Market Focus: The company's heavy reliance on the dental solutions market may limit diversification opportunities. Economic downturns can lead to reduced consumer spending on dental care, impacting revenues.

 High Competition: The dental products market is fragmented with numerous.
- players, which could lead to pricing pressures and reduced profit margins as competition intensifies.

 Forex Risk: As Laxmi Dental operates internationally, fluctuations in currency
- Forex Risk: As Laxmi Dental operates internationally, fluctuations in currency exchange rates can affect profitability, especially given its export activities to over 95 countries
- Brand Perception and Network Dependence: The company's success heavily depends on expanding its dental network and maintaining positive brand perception among dental professionals. Any negative shifts in these areas could impact sales and growth prospects.

Valuation and Outlook



Laxmi Dental Limited IPO is expected to be priced between ₹407 to ₹428 per share. At this price, the company is valued at Price-to-Earnings (P/E) ratio of 89.16x whereas the industry average is 94.02x.

Name of Company	Face Value (₹ per share)	Total Income, for Fiscal 2024 (in ₹ million)	EPS (₹) Basic	EPS (C) Diluted	NAV (₹ per share)	P/E	RoNW (%)
Laxmi Dental Limited	2	1,952.64	4.8	4.8	8.63	NA	78.78
Peer Group							
Poly Medicure	5	14,345.44	26.92	26.9	153.22	94.02	19.05

The last three financial years, the company reported total income and net profit (or loss) as followers: Rs. 1360 or ore / Rs. -710 erore in FV.24. Rs. 18.58 & crore / Rs. -4.6 crore in FV.24. Rs. 18.58 & crore / Rs. -4.6 crore in FV.24. For the first half of FV.25, it earned Rs. 18.20 crore net profit on Rs. 17.90 crore income, Average EPS was Rs. 1.55, and RoNW was 22.77%, with a PfE of 64.65 based on FV.25 estimates.

"Call us on 8448899576" to find out whether or not you should apply.



Disclaimer:

This Report is for the personal information of the authorised recipient(s) and is not for public distribution and should not be reproduced or redistributed to any other person or in any form without prior permission of Ganesh Stock. The information provided in the report is from publicly available data, which we believe, are reliable but does not taken as an indication or guarantee of future performance/ assurance of returns. The Report also includes analysis and views of their team. The Report is purely for information purposes and does not construe to be investment recommendation/advice or an offer or solicitation of an offer to buy/sell any securities. Investment in Securities Market is subject to Market Risk.

Accordingly, Ganesh Stock or any of its connected persons including its directors or subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained, views and opinions expressed in this publication.

Investors should not solely rely on the information contained in this Report and must make investment decisions based on their own investment objectives, judgment, risk profile and financial position. The recipients of this report may take professional advice before acting on this information.

